Skip to content

King Pharmaceuticals KG Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration

Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration at other companies

Security National Financial Corporation logo
Security National Financial CorporationSNFCA
$568.3K-82.1%
IBT
IbottaIBTA
$74.9M
ROC
Rank One Computing ROC
$2.04K
Popular logo
PopularBPOP
$627.73M-5.2%
ESAB logo
ESABESAB
$2.2M-56.9%
VAN
Vivani MedicalVANI
$47.35M0.0%

Other financials

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M
Total equity$121.4M+2,773%
Total assets$964.2M

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation

See full
Market cap$70.42M-71.3%
Enterprise value$184.93M-52.3%
P/E1.2×
P/S1.6×-27.7×

Profitability

See full
Net margin131.5%

Returns & leverage

See full
Return on equity90.8%
Debt / equity1.5×

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's deferred tax assets operating loss carryforwards not subject to expiration.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is King Pharmaceuticals's deferred tax assets operating loss carryforwards not subject to expiration?
King Pharmaceuticals (KG) reported deferred tax assets operating loss carryforwards not subject to expiration of $88.7M in Q1 2026.